Buy enzalutamide tablets online
Package details: 56 tablets
Manufacturer: Astellas Pharma Inc., Japan
Active ingredient: enzalutamide (chemical formula C21H16F4N4O2S)
Medical effect: Xtandi tablets are effective for the treatment of castration-resistant prostate cancer and metastatic prostate cancer.
Contraindications and precautions: never use in pregnant or breastfeeding women. Do not use for patients with a history of convulsive disease such as epilepsy, patients with the predisposition to convulsive seizure (having coexisting disease such as brain damage or stroke, or have a history of it), patients with a history of interstitial lung disease or the current disease.
Pay attention when driving a car or operating dangerous mechanisms while taking this medicine as in some rare cases it may cause seizures.
Since this medicine may cause interstitial lung disease, initial symptoms such as shortness of breath, respiratory distress, cough, fever, etc. should be constantly monitored and chest X-ray should be regularly performed while using this medicine.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Xtandi tablets 40 mg from Japan for prostate cancer (enzalutamide)
For adults, take 4 tablets (160 mg of the active ingredient) at a time, once a day. This medicine is also available in a form of the 80 mg of active ingredient.
How effective are Xtandi tablets 40 mg from Japan for prostate cancer (enzalutamide)? Buy enzalutamide tablets online
Xtandi tablets contain enzalutamide, a nonsteroidal antiandrogen. It works by inhibiting binding of androgen (male hormone) against androgen receptors which exist in prostate tissues. Consequently, Xtandi tablets show significant anti-tumor effects. Also, this medicine exerts effectiveness by inhibiting multiple proliferative pathways in prostate cancer cells.
Who should take Xtandi tablets 40 mg from Japan?
Xtandi tablets are recommended for patients with castration-resistant prostate cancer and metastatic prostate cancer. Clinical trials showed 30% reduction in the risk of death for patients who have not yet received chemotherapy and 81% reduction in risk of radiographic progression or death (T. M. Beer, A. J. Armstrong et al. “Enzalutamide in Metastatic Prostate Cancer before Chemotherapy”. The New England Journal of Medicine, 2014; 371: 424-433). Also, Xtandi tablets can be used as an antiandrogen in feminizing hormone therapy for transgender women. However, it should never be used for pregnant women as it may cause fetal harm.